Background No adjuvant treatment has been established for patients who remain at high
risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We …

IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance
in patients with hepatocellular carc Page 1 IMbrave050: Phase 3 study of adjuvant atezolizumab …

Background Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …

Background Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …

Background & Aims IMbrave150 demonstrated that atezolizumab plus bevacizumab led to
significantly improved overall survival (OS) and progression-free survival (PFS) compared …

Hepatocellular carcinoma recurs in 70–80% of cases following potentially curative resection
or ablation and the immune component of the liver microenvironment plays a key role in …

Objective: Evaluation of the efficacy and safety of atezolizumab/bevacizumab in a real-world
HCC cohort, including patients with impaired liver function and prior systemic therapy …

Summary Background and Aims Phase III trials have established atezolizumab plus
bevacizumab as the novel standard of care for patients with unresectable hepatocellular …

Background IMbrave150 has established the superiority of atezolizumab plus bevacizumab
over sorafenib in patients with unresectable hepatocellular carcinoma (HCC). Methods We …

Abstract On May 29, 2020, the FDA approved atezolizumab for use in combination with
bevacizumab, for the treatment of adult patients with unresectable locally advanced or …